Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients

[1]  Carsten Gnewuch,et al.  Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. , 2010, International journal of antimicrobial agents.

[2]  T. Wiemken,et al.  Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. , 2010, Chest.

[3]  A. Martín-Suárez,et al.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. , 2010, British journal of clinical pharmacology.

[4]  V. Tam,et al.  Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. , 2009, International journal of antimicrobial agents.

[5]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  E. Tschernko,et al.  Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion , 2009, Anesthesiology.

[7]  P. Viale,et al.  Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients , 2009, Antimicrobial Agents and Chemotherapy.

[8]  V. Tam,et al.  Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. , 2008, The Journal of antimicrobial chemotherapy.

[9]  R. Moellering,et al.  Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  G. Drusano,et al.  Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity , 2008, Antimicrobial Agents and Chemotherapy.

[11]  Á. Soriano,et al.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Joshua A. Doherty,et al.  A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. , 2007, Clinical therapeutics.

[13]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[14]  A. Wong-Beringer,et al.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.

[15]  N. V. Jiménez-Torres,et al.  Population pharmacokinetic parameters of vancomycin in critically ill patients , 2006, Journal of clinical pharmacy and therapeutics.

[16]  P. Hoffmeyer,et al.  High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion , 2004, Journal of clinical pharmacy and therapeutics.

[17]  T. Similowski,et al.  Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study , 2001, Antimicrobial Agents and Chemotherapy.

[18]  Jerome J. Schentag,et al.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. , 2000, International journal of antimicrobial agents.

[19]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. Jeurissen,et al.  A higher dose of vancomycin in continuous infusion is needed in critically ill patients. , 2011, International journal of antimicrobial agents.

[21]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  M. Kitzis,et al.  Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.